BTIG Reiterates Buy on Faeth Therapeutics, Maintains $55 Price Target
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsReiterationPrice Target
BTIG analyst Jeet Mukherjee reiterates Faeth Therapeutics (NASDAQ:FTH) with a Buy and maintains $55 price target.
BTIG analyst Jeet Mukherjee reiterates Faeth Therapeutics (NASDAQ:FTH) with a Buy and maintains $55 price target.